Archive


Warning: getimagesize(/home/isofolme/public_html/wp-content/uploadshttps://www.pharmasalmanac.com/hubfs/2236109/PA_logo_Hoz_2019.svg): failed to open stream: No such file or directory in /home/isofolme/public_html/wp-content/themes/joyn/includes/plugins/aq_resizer-1x.php on line 80

  • Pharma’s Almanac – Round table

    Our CEO, Anders Rabbe, was featured twice in Pharma’s Almanac Q3 issue in its “Round table” segment. He discussed the…

    by

  • Published abstract at ESMO

    Published abstract at ESMO “Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic…

    by

  • Poadcast – “The Cancer Gene”

    Listen to recent episode from The Cancer Gene podcast features Anders Rabbe, CEO of Isofol, discussing colorectal cancer and the…

    by
  • aside

    Isofol has participated in the Empowered Patient Podcast

    In honor of World Cancer Day on February 4, we would like to share a podcast where Anders Rabbe, CEO…

    by
    0
  • aside

    Isofol Announces the Appointment of Robert Marchesani as an Advisor to its Board of Directors

    GOTHENBURG, Sweden, November 16, 2018 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the appointment of…

    by
  • aside

    Isofol presents a poster at ESMO 2018 Congress in Germany

    Isofol is attending the ESMO 2018 Congress in Germany, which is taking place between October 19-23. During Sunday the poster, “ISO-CC-005;…

    by
  • aside

    Patent approved in the United States for Isofol’s drug candidate arfolitixorin

    The patent now approved in the United States expires in 2037 and covers both the Active Pharmaceutical Ingredient (arfolitixorin hemisulfate),…

    by
  • aside

    DNB initiates monitoring of Isofol

    The Norwegian Bank (DNB) has initiate the monitoring of Isofol Medical AB.     For more information, please contact: Anders…

    by
  • aside

    Redeye and Isofol are inviting to the live broadcast of pre-ASCO on May 28th

    In connection to this year’s major cancer congress ASCO (American Society of Clinical Oncology) in Chicago in June, Redeye brings…

    by
  • aside

    Isofol announces that an abstract with new research results has been published for this year’s ASCO congress in Chicago

    Isofol Medical AB (publ) announces that a scientific abstract has been published for this year’s annual Congress of the American…

    by
  • aside

    Isofol reports FDAs feedback from the ongoing special protocol assessment (SPA) process

    In March 2018, Isofol Medical AB (publ) submitted a Special Protocol Assessment (SPA) to the United States Food and Drug…

    by
  • aside

    Isofol announces that an abstract describing a genetic prediction of treatment response in CRC treatment to be unveiled at ASCO 2018

    Isofol Medical AB (publ) announces that an abstract describing correlation between expression levels of folate-related genes in tumours with progression-free…

    by
  • aside

    Invitation to a specialist investor event focusing on late-stage drugs for colorectal cancer with Redeye and Isofol Medical

    On April 10th, Redeye will organize an investor specialist event focusing on late-stage drugs aimed to treat colorectal cancer. Isofol…

    by
  • aside

    Isofol Medical has selected arfolitixorin-dose for the phase III pivotal study ISO-CC-007

    The selected dose for the drug candidate arfolitixorin of 120 mg/m2, (approximately 200 mg for an adult male) is based…

    by
  • aside

    Isofol reports successful outcome from the scientific advice with the EMA

    Isofol Medical AB (publ) has received positive feedback in scientific advice from the European Medicines Agency (EMA) regarding its candidate…

    by
  • aside

    Isofol’s CEO, directors and employees converts stock – and employee options and subscribe shares for SEK 7 655 136

    The incentive program consisting of stock – and employee options in Isofol Medical AB, which was initiated in 2012 with…

    by